Clinical trials: Urinary Symptoms
Overactive Bladder (OAB)
RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder
This Phase 2b study is a prospective, multicenter, double blind, randomized, placebo and sham controlled trial to assess the safety, efficacy and dose response of NT 201 delivered by the Vibe System in participants with…
- Trial name
- RELIEVE (NCT07553065)
- Testing
- NT 201 200U and Vibe System, NT 201 300U and Vibe System
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Vensica Therapeutics Ltd.
Adult Nocturnal Enuresis, Urinary Incontinence (UI)
This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their…
- Trial name
- PUREST (NCT06666426)
- Testing
- PureWick System, Hollister Female Urinary Pouch External Collection Device
- Where
- 15 sites in United States
- Volunteers
- 171 people
- Sponsor
- C. R. Bard
Healthy Volunteers, Enteric Hyperoxaluria
Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects
The first stage of this study is a prospective, adaptive, Phase 1, first-in-human, randomized, controlled study evaluating safety, tolerability, and pharmacodynamics of NOV-001 in adult healthy volunteers.
- Trial name
- NCT04909723
- Testing
- NOV-001, NB1000S, NB2000P
- Where
- 20 sites in United States, Canada
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novome Biotechnologies Inc
Urinary Incontinence, Stress
Duloxetine Stress Urinary Incontinence Efficacy and Safety Study
Study F1J-MC-SBBU will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.
- Trial name
- NCT00475397
- Testing
- Duloxetine
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Urinary Bladder, Overactive
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
The study is intended to test the safety, tolerability, and efficacy of long-term treatment with YM178 in patients with overactive bladder symptoms.
- Trial name
- NCT00840645
- Testing
- YM178
- Where
- 2 sites in Japan
- Volunteers
- 204 people
- Sponsor
- Astellas Pharma Inc
Urologic Diseases, Urinary Bladder, Overactive
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of…
- Conditions
- Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
- Trial name
- BEYOND (NCT01638000)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 217 sites in Armenia, Austria and 31 more
- Volunteers
- 1,887 people
- Sponsor
- Astellas Pharma Europe Ltd.
Prostatic Hyperplasia
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of…
- Trial name
- NCT02244229
- Testing
- Tamsulosin, Finasteride
- Volunteers
- 403 people
- Sponsor
- Boehringer Ingelheim
Overactive Bladder
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine.
- Trial name
- NCT01302067
- Testing
- Fesoterodine 8mg, Fesoterodine 4mg
- Where
- 293 sites in United States, Argentina and 25 more
- Volunteers
- 2,012 people
- Sponsor
- Pfizer
Overactive Bladder, Neurogenic Detrusor Overactivity
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after taking a single oral dose.
- Trial name
- NCT01539707
- Testing
- Solifenacin succinate suspension 5 mg
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Underactive Bladder
A Study of ASP8302 in Participants With Underactive Bladder
The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in…
- Trial name
- NCT03702777
- Testing
- ASP8302
- Where
- 29 sites in Germany, Japan and 4 more
- Volunteers
- 135 people
- Sponsor
- Astellas Pharma Europe B.V.
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
A study to evaluate the safety of the co-administration of solifenacin succinate with tamsulosin hydrochloride in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO).
- Trial name
- NCT00507455
- Testing
- solifenacin succinate, tamsulosin hydrochloride
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 222 people
- Sponsor
- Astellas Pharma Inc
Hematuria, Cystoscopy
Bladder EpiCheck European Haematuria Study
The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria…
- Conditions
- Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06818136
- Testing
- Bladder EpiCheck
- Where
- 5 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Nucleix Ltd.
Nocturia
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women
The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult women during 12 weeks treatment
- Trial name
- NOC (NCT01684800)
- Testing
- A. Desmopressin 10 microgram, B: Desmopressin 25 microgram
- Where
- 36 sites in Japan
- Volunteers
- 178 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Stress Urinary Incontinence
Use of the Leva Incontinence System in Treating Bladder Incontinence.
This open-label proof-of-concept study is designed to evaluate the impact of the leva digital incontinence system on the treatment of stress and mixed urinary incontinence in women over a six week period.
- Trial name
- NCT03536923
- Testing
- Leva Incontinence System For Pelvic Floor Muscle strengthening
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Renovia, Inc.